Indeed, dabrafenib and trametinib were granted accelerated approval by the FDA for the treatment of adult and pediatric patients (older than six years of age) with unresectable or metastatic solid tumors harboring a BRAF V600E mutation, provided that the patient both progressed on prior treatment and had no satisfactory alternative therapeutic options; however, CRC patients were excluded [26]. Here, BRAF is linked to colorectal carcinoma.